Emerging Medtech Companies from LSI Europe ’25 to Watch

LSI Europe ’25 has wrapped, marking the fourth Emerging Medtech Summit in Europe and the 11th globally. Nearly 1,000 industry leaders convened in London, generating thousands of meetings and countless opportunities. In the days since, conversations about deals, partnerships, and future collaborations have already started to surface.

This summit is about more than presentations; it is where investors, strategics, and entrepreneurs come together to shape the future of healthcare. With more than 200 startups presenting their technologies, commercial milestones, and fundraising goals, the event spotlighted the breadth of innovation happening across the industry.

Emerging Medtech Companies to Watch

Among those presenting, five emerging medtech companies captured particular attention for their market opportunities, recent progress, and potential to disrupt entrenched approaches. Below, we look at the numbers and context behind each one.

Del Medtech: Pulsed-Field Ablation Beyond the Heart

Speaker: Dr. Steven Mickelsen

Stage: Series A

Currently Raising: $10 million

Del Medtech is the latest venture from Dr. Steven Mickelsen, well known for his previous leadership roles at FARAPULSE, Field Medical, and Atraverse Medical. At LSI Europe, he introduced Del Medtech’s vision to extend pulsed-field ablation (PFA) technologies beyond cardiology into oncology and men’s and women’s health.

The company estimates it is pursuing a $1.5 billion market opportunity, competing with firms like AngioDynamics and Pulse Biosciences. Potential clinical indications are compelling:

• Prostate cancer: ~3 million men in the U.S.
• Cervical dysplasia: ~1.3–2.6 million women
• Endometrial hyperplasia: ~3–5 million women

These prevalence numbers highlight the disruptive potential of PFA in new therapeutic areas. Del Medtech’s approach leverages extensive expertise in energy-based therapies and could align with surgical robotics, a field already seeing strong adoption in many of the same indications.

May Health: Redefining PCOS Treatment

Speaker: Colby Holtshouse

Stage: Series B

Currently Raising: $12 million

Polycystic ovary syndrome (PCOS) is among the most common causes of infertility related to ovulation. Traditional options include drug therapy, invasive ovarian drilling, and in vitro fertilization (IVF). These solutions carry risks such as multiple pregnancies, procedural invasiveness, and significant financial burden.

May Health is developing a minimally invasive, office-based procedure designed to match the effectiveness of ovarian drilling while minimizing complications. The aim is to enable natural conception without the risks tied to more aggressive interventions.

The scale of the problem is immense. According to the World Health Organization, 6–13% of reproductive-aged women worldwide have PCOS, translating to 240–520 million individuals. Compounding the issue, as many as 70% of women remain undiagnosed.

In this environment, a simpler, more accessible treatment option could shift the paradigm. If successful, May Health could provide a pathway that addresses both the underdiagnosis challenge and the limitations of current interventions.

InFlo Medical: Portable ECMO for Critical Care

Speaker: Nicholas Williams

Stage: Series A

Currently Raising: $6 million

Extracorporeal membrane oxygenation (ECMO) has become an essential tool for supporting patients with severe cardiorespiratory failure. In the U.S., around 17,500 patients are placed on ECMO annually. Yet many more might benefit if portable solutions were available for prehospital or inter-facility use.

InFlo Medical’s MOBYBOX system addresses this gap. The technology provides continuous extracorporeal life support across care settings, including transport scenarios, without circuit disruption.

The potential market is significant. Patients with refractory cardiac arrest and severe cases of acute respiratory distress syndrome (ARDS) could benefit from earlier ECMO deployment. Combined, these populations represent between 160,000 and 210,000 patients annually.

If InFlo can bring its portable ECMO technology to scale, it could expand access to a therapy that is often limited to major hospital centers, creating life-saving possibilities in new contexts.

Nyxoah: Tackling Sleep Apnea with Neuromodulation

Speaker: Olivier Taelman

Stage: IPO

Capital Raised: $320 million

Sleep apnea is one of the most underdiagnosed yet impactful conditions in global health. Nyxoah has developed Genio, a minimally invasive, battery-free hypoglossal nerve stimulation implant for obstructive sleep apnea (OSA). Controlled externally by a wearable, Genio offers an alternative to continuous positive airway pressure (CPAP), the longstanding first-line therapy.

OSA affects nearly one billion adults worldwide, with about 10% of that population residing in the United States. CPAP therapy dominates the treatment landscape, with roughly 80% of patients prescribed the therapy. However, adherence is a persistent problem. An estimated 30% of U.S. patients fail to meet compliance standards, largely due to discomfort.

The financial implications of nonadherence are severe, with increased morbidity, mortality, and healthcare costs. With a global CPAP and diagnostic device market valued at $6.2 billion in 2024, Nyxoah’s Genio device is well-positioned to capture patients in need of a more tolerable solution.

ART MEDICAL: Smarter ICU Nutrition and Infection Control

Speaker: Ori Braun

Stage: Series C

Currently Raising: $30 million

Critical care environments face two major, often overlooked challenges: malnutrition and ventilator-associated pneumonia (VAP). ART MEDICAL has developed the smART+ Platform to address both through continuous monitoring and real-time adjustments to nutritional support.

The platform has demonstrated the ability to reduce intensive care unit (ICU) stays and mechanical ventilation duration by 3.3 days on average. It delivers up to 100% feeding efficiency via reflux detection, dynamic nutritional compensation, and tube position monitoring.

The scale of the issue is vast:

• There are 5–6 million ICU admissions annually in the U.S.
• Roughly 50% of these patients are malnourished or at risk of becoming malnourished during their stay.
• Up to 30% of mechanically ventilated ICU patients develop VAP.

For every one million ICU patients, these two complications alone carry an estimated direct cost burden of $1.6 billion. ART MEDICAL’s technology directly addresses this financial and clinical gap, positioning it as a company to watch in intensive care innovation.

Why These Companies Stand Out

The five companies highlighted above represent diverse areas of clinical innovation, from oncology to reproductive health, respiratory support, sleep medicine, and critical care. What unites them is their potential to transform standards of care and disrupt existing markets.

Del Medtech is aiming to extend pulsed-field ablation into new indications. May Health is rethinking infertility treatments for PCOS. InFlo Medical is making ECMO more portable and accessible. Nyxoah is addressing the unmet needs in sleep apnea adherence. ART Medical is advancing ICU care through smarter nutrition and infection prevention.

Together, these emerging medtech companies illustrate the creativity, ambition, and clinical focus driving the industry forward.

Want to see what’s next? Join us at LSI USA ’26, where presenting companies will showcase new technologies, funding wins, and clinical progress shaping the future of medtech.